GENOME RESEARCH LIMITED

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Deloitte LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In assessing whether the going concern assumption is appropriate, the Trustees take into account all available information which is at least, but is not limited to, twelve months from the date when the financial statements are authorised for issue. GRL do not commit to set levels of activity on third party awards. In the event that we wished to support a study beyond the terms of the grant, we would only do this if there were sufficient budget in the core award. Trading contracts are agreed on commercial terms, in such a way that, as a minimum, all costs are recovered and GRL is not exposed to significant working capital deficits. The year ended 30 September 2025 was the fourth year in a five year award from GRL's parent company, Wellcome. Management have sufficient discretion over spend to ensure expenditure remains within budget over the five year period. After considering the 2025-26 budget, the 5 year award from Wellcome for 2021-2026 and the letter of support from Wellcome confirming that funding will be provided to pay any liabilities for the period up to twelve months following approval of the financial statements, the Trustees are satisfied that it is appropriate to adopt the going concern basis in preparing the financial statements of GRL.”

Group structure

1. GENOME RESEARCH LIMITED · parent
   1. Genome Research Trading Limited 1% · England and Wales · Facilities Management
   2. Hinxton Hall Limited 0.5% · England and Wales · Education / Facilities Management
   3. Genome Research Pension Trustee Limited 1% · England and Wales · Dormant
   4. GRL Construction Limited 1% · England and Wales · Construction
   5. Base RX Limited 1% · England and Wales · Scientific Research

Significant events

• “This year has marked a pivotal phase in our progress towards implementing Genome Research Limited's (operating as the Wellcome Sanger Institute) ten-year strategy, as we evolve to continue generating high-impact knowledge and amplify our global influence.”
• “Strategic planning has been a key activity across the organisation this year, focused on defining and strengthening the capabilities that underpin the delivery of our science: One focus has been on developing our Al for science capabilities by building on Sanger's unique strengths of large-scale data generation, foundational biological insights and computational innovation to unlock the potential of generative biology.”
• “In May 2025, the data centre experienced a critical incident that damaged some storage systems, impacting a number of scientific projects.”
• “On 1 February 2025, as part of the transition of Campus management to a new commerical management company, the lease of the Wellcome Genome Campus from the Wellcome Trust to GRL was varied in such a way that GRL surrendered all land and buildings on the Campus which were not occupied by GRL.”
• “Net loss on surrender of leased assets of £6.3 million”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +4.2%

  £158,181,000 → £164,887,000

• Cash

  +8.6%

  £15,359,000 → £16,681,000

• Net assets

  +1.3%

  £270,238,000 → £273,699,000

• Employees

  +0.4%

  1,296 → 1,301

• Wages

  +2.1%

  £70,026,000 → £71,505,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers